This study is comprised of a 104 week treatment period beginning on Day 1 of study drug administration and a 30-day follow-up period or permanent termination of clinical development of the product, whichever is earlier.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01711814?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
